Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Jade Biosciences Inc (JBIO)

146 + Investors. Track Smart Money conviction in JBIO. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +30
Streak
5Q ▲
Buyers last Q
71%

Smart Money Signals — JBIO

Based on 148 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 5 quarters in a row

last 6Q
For 5 consecutive quarters, more hedge funds added JBIO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
148 hedge funds hold JBIO right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +114% more funds vs a year ago

fund count last 6Q
+79 new funds entered over the past year (+114% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 71% buying

109 buying45 selling
Last quarter: 109 funds were net buyers (50 opened a brand new position + 59 added to an existing one). Only 45 were sellers (25 trimmed + 20 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+23 vs last Q)

new funds entering per quarter
Funds opening a new JBIO position: 9 → 36 → 27 → 50. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔄

Mostly new holders — 56% entered in last year

■ 3% conviction (2yr+) ■ 41% medium ■ 56% new
Only 5 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💰

Value +124% but shares only +45% — price-driven

Value
+123%
Shares
+45%
Last quarter: the total dollar value of institutional holdings rose +124%, but actual share count only changed +45%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

68 → 9 → 36 → 27 → 50 new funds/Q
New funds entering each quarter: 9 → 36 → 27 → 50. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🌱

Early stage — 95% of holders entered in last year

■ 5% veterans ■ 0% 1-2yr ■ 95% new
Of 150 current holders: 143 (95%) entered in the past year, only 7 (5%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
✅

Strong quality — 33% AUM from major funds

33% from top-100 AUM funds
38 of 146 holders rank in the top 100 by AUM, accounting for 33% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
5.6
out of 10
Moderate Exit Risk
Exit risk score 5.6/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — JBIO

In 2026 Q2, 109 hedge funds were net buyers of JBIO (50 opened a new position, 59 added to an existing one), while 45 reduced or exited (25 trimmed, 20 sold completely) — a 71% buyer ratio, indicating clear institutional accumulation. This marks 5 consecutive quarters of net institutional buying — a persistent conviction signal. 33% of total institutional value in JBIO is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +30 funds (more new holders than closures). Total institutional holders: 148.

Hedge Fund Ownership: JBIO

How many hedge funds hold JBIO — quarterly history vs. share price
Quarterly hedge fund ownership of JBIO vs. share price

Market Analysis: JBIO

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: JBIO

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Loading signal freshness…
Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

10 top-rated funds 6 high-conviction
Consensus
4.5
/ 10
breadth
×
Elite
4.4
/ 10
conviction
Hedge Fund Positioning: JBIO
146 + Investors

Track Smart Money conviction in JBIO. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 146 118 23.73%
13F Shares 72M 50M 44.98%
Total Value $1.60B $715M 123.94%
New Positions 50 27 +23
Increased Positions 58 39 +19
Closed Positions 20 14 +6
Reduced Positions 24 33 -9
Total Calls 1 1 -
Total Puts 3 4 -25.0%
PUT/CALL Ratio 3.0 4.0 Bearish

Statistics: JBIO

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

146 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in JBIO. Verified SEC 13F-HR filings.

QUARTER:
Top 25 JBIO holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Versant Venture Management, LLC 13.55% 991,783 $22.0M
2 Remedium Capital Partners, LLC 7.76% 1,577,750 $35.1M
3 Fairmount Funds Management LLC 6.69% 4,553,494 $101.2M
4 Avidity Partners Management LP 6.05% 1,700,708 $37.8M
5 Acorn Capital Advisors, LLC 5.98% 986,760 $21.9M
6 Foresite Capital Management VI LLC 3.07% 886,667 $19.7M
7 Venrock Adviser, LLC 2.17% 3,220,364 $71.6M
8 Bellevue Group AG 1.43% 3,057,996 $67.9M
9 Samsara BioCapital, LLC 1.34% 736,237 $16.4M
10 Verdad Advisers, LP 1.20% 56,384 $1.3M
11 Paradigm Biocapital Advisors LP 1.19% 2,857,405 $63.5M
12 Soleus Capital Management, L.P. 1.19% 1,550,690 $34.5M
13 Logos Global Management LP 1.08% 1,125,000 $25.0M
14 Ikarian Capital, LLC 1.02% 427,349 $9.5M
15 Affinity Asset Advisors, LLC 0.84% 840,350 $18.7M
16 Ra Capital Management, L.P. 0.71% 3,671,083 $81.6M
17 Atle Fund Management AB 0.53% 88,556 $2.0M
18 Opaleye Management Inc. 0.29% 145,000 $3.2M
19 Harvest Investment Services, LLC 0.22% 62,983 $1.4M
20 Baker BROS. Advisors LP 0.14% 1,230,426 $27.3M
21 Sofinnova Investments, Inc. 0.12% 107,391 $2.4M
22 Virtus Investment Advisers, LLC 0.11% 21,329 $474K
23 Polar Capital Holdings Plc 0.10% 1,846,982 $41.0M
24 Seven Grand Managers, LLC 0.09% 100,000 $2.2M
25 Adage Capital Partners GP, L.L.C. 0.06% 1,910,812 $42.5M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Jade Biosciences Inc (JBIO)

What does the Smart Money Trend signal show for JBIO?

Buying streak — 5 quarters in a row: For 5 consecutive quarters, more hedge funds added JBIO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for JBIO?

More buyers than sellers — 71% buying: Last quarter: 109 funds were net buyers (50 opened a brand new position + 59 added to an existing one). Only 45 were sellers (25 trimmed + 20 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for JBIO holders?

Strong quality — 33% AUM from major funds: 38 of 146 holders rank in the top 100 by AUM, accounting for 33% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held JBIO?

Mostly new holders — 56% entered in last year: Only 5 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →